RLMD
Relmada Therapeutics Inc

2,165
Mkt Cap
$636.68M
Volume
1.57M
52W High
$7.51
52W Low
$0.243
PE Ratio
-4.13
RLMD Fundamentals
Price
$6.07
Prev Close
$6.25
Open
$6.50
50D MA
$4.53
Beta
0.48
Avg. Volume
653,706.18
EPS (Annual)
-$1.45
P/B
5.15
Rev/Employee
$0.00
$97.68
Loading...
Loading...

Earnings Recap

Relmada Therapeutics Inc. reported a net loss of $57,385,163, or $1.45 per common share, for the year ended December 31, 2025, and had negative operating cash flows of $45,786,988.

Bullish

Relmada Therapeutics Inc. diversified its pipeline with NDV-01 and sepranolone, showing favorable Phase 2 NDV-01 data and FDA alignment for Phase 3, while securing significant funding to support ongoing operations.

Bearish

Relmada Therapeutics Inc. faces substantial losses and uncertain future profitability, with new drug candidates in early, high-risk development; intense competition and evolving healthcare reforms further challenge its business.

Latest RLMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.